Did Michael Callahan "supervise treatments" of COVID-19 patients in Wuhan?

Important information on Michael Callahan’s activities in Wuhan in the earliest stages of the COVID-19 pandemic has emerged that paints a very different picture than what I have heard to date. I came upon the information from George Webb on Twitter. Mr. Webb credited Mark Kulacz (Housatonic Live).

The information is a written reply from Robert Malone to Dr. Erin Smith in Australia which you can read on Medium. Dr. Smith’s profile says “I am an Associate Professor in Disaster and Emergency Response in Australia.” Erin wrote “Last night some of the world experts on COVID-19 came together: These are their thoughts” on March 21, 2020.”

Previously Michael Callahan had been described as having analyzed data from COVID patients while he was in China. As the AP reported, “Callahan said he and the Chinese doctors analyzed the medical records of more than 6,000 hospitalized patients.”

Malone’s reply to Smith alters the facts substantially on Callahan’s perceived role in Wuhan as an observer. Malone wrote: “…my colleague Dr. Michael Callahan ( who currently reports directly to the ASPR in US) has supervised treatment (emphasis mine) of well over 6000 cases of COVID19, was in country in the PRC assisting, …”

The information substantially alters my perception that Callahan had been simply observing patients in Wuhan, and that he had somehow managed to collect data from Chinese hospitals. If I am reading this right, Michael Callahan was “supervising treatment” of Chinese COVID-19 patients in China. 6,212 patients, as reported by Brenden Borrell.

Here’s the full text of the from Mr. Malone to Dr. Smith, dated April 01, 2020:

Mr. Malones report of Michael Callahan “supervising treatment” raises the possibility that Callahan directed treatment plans, or trials of treatments, of over 6,000 COVID-19 patients in China.

Borrel wrote: “In reviewing 6212 COVID-19 patient records, the doctors noticed that many survivors had been suffering from chronic heartburn and were on famotidine rather than more-expensive omeprazole (Prilosec), the medicine of choice both in the United States and among wealthier Chinese. Hospitalized COVID-19 patients on famotidine appeared to be dying at a rate of about 14% compared with 27% for those not on the drug, although the analysis was crude and the result was not statistically significant.”

Again, making the data sound like an “observation,” rather than test results.

Did Michael Callahan direct Chinese physicians to use Pepcid (famotidine) to treat COVID-19? Callahan could possibly have received data on famotidine from the DOMANE system at Alchem Laboratiries in Alchua, Florida.

The timeline on the DOMANE system which came online at Alchem is a bit mysterious. I have called for it to all aspects of DOMANE to be declassified.

The exact dates surrounding DOMANE and the “discovery” of famotidine are extremely important. I would rather have facts than speculate.

Brenden Borrell reported that “Michael Callahan, an infectious disease expert, was working with Chinese colleagues on a longstanding avian flu collaboration in November when they mentioned the appearance of a strange new virus.”

By December 11, a document on DOMANE had been prepared by DTRA. This means that the DOMANE system could have been used prior to the January 10, 2020 date, when China sent the SARS-CoV-2 virus sequence to researchers around the world, including Robert Malone at Alchem. Alchem could have had the genetic sequence for the “Wuhan virus” prior to January 10, 2020, and identified famotidine and possibly also omeprazole as aantidotes, then passed the information on to Callahan, who supervised the treatment plans or tests.

This is speculation on my part. The status quo perception is that 600 COVID patients just happened to be taking famotidine in Wuhan hospitals, and that the patients taking famotidine died at a lower rate than COVID patients taking another similar product, omeprazole.

Later, after Callahan’s return to the United States, Callahan reported his famotidine findings to Robert Kadlec at ASPR. Kadlec ultimately contracted for trials of hydroxychloroquine and famotidine + HCQ trials at Alchem.

Charles Wright